+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bipolar Disorder Therapeutics Market by Therapeutics, Mechanism Of Action, Drug Administration Route, Patient Age Group, End User, Treatment Duration - Global Forecast 2025-2030- Product Image
Bipolar Disorder Therapeutics Market by Therapeutics, Mechanism Of Action, Drug Administration Route, Patient Age Group, End User, Treatment Duration - Global Forecast 2025-2030- Product Image
Sale

Bipolar Disorder Therapeutics Market by Therapeutics, Mechanism Of Action, Drug Administration Route, Patient Age Group, End User, Treatment Duration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010914
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bipolar Disorder Therapeutics Market grew from USD 6.01 billion in 2023 to USD 6.37 billion in 2024. It is expected to continue growing at a CAGR of 5.45%, reaching USD 8.73 billion by 2030.

The scope of the bipolar disorder therapeutics market primarily encompasses pharmacological interventions, including mood stabilizers, antipsychotics, and adjunctive therapies used to manage bipolar disorder symptoms. This market is driven by the increasing prevalence of bipolar disorder, a chronic mental health condition characterized by extreme mood swings, necessitating ongoing management and medication. The application of these therapeutics extends across different phases of the disorder, including acute manic, depressive, and maintenance phases, with treatment modalities often tailored based on patient-specific needs. End-users comprise hospitals, psychiatric clinics, and outpatient facilities, with a rising trend towards personalized medicine enhancing the therapeutic landscape. Key growth factors influencing the market include advancements in pharmacogenomics facilitating targeted therapy approaches, increasing societal awareness, and greater investment in mental health infrastructure. The rise in telepsychiatry services also presents a potential opportunity for expanding therapeutic access, particularly in underserved areas. However, market growth is challenged by factors such as the high cost of innovative drugs, side effects associated with medication, and the stigma surrounding mental illnesses that may hinder treatment adherence. Furthermore, regulatory hurdles and the need for a precise diagnosis present persistent challenges. Despite these limitations, significant opportunities exist in the development of novel treatment regimes, particularly those leveraging biotechnology and neurostimulation techniques. Research into gut-brain axis interactions and the development of biosensors for real-time mood monitoring could pioneer innovations in treatment strategies. The competitive market is characterized by collaborative efforts among pharmaceutical companies, with a focus on mergers and acquisitions to broaden therapeutic portfolios. To foster business growth, companies are recommended to invest in R&D for therapies with fewer side effects and to explore partnerships for enhancing distribution networks. Balancing innovation with affordability will be critical in broadening market reach and addressing the therapeutic gaps currently faced in effectively managing bipolar disorder.

Understanding Market Dynamics in the Bipolar Disorder Therapeutics Market

The Bipolar Disorder Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Emerging digital health technologies enabling more efficient management of bipolar disorder
    • Growing investment in biotechnology and pharmaceutical R&D driving innovation in bipolar disorder treatments
    • Expansion of healthcare infrastructure and accessibility improving patient outcomes for bipolar disorder
    • Patient advocacy groups influencing the development and approval of new bipolar disorder medications
  • Market Restraints
    • Regulatory hurdles and lengthy approval processes for new bipolar disorder therapeutic drugs
    • Insufficient funding and investment in bipolar disorder research and development affecting innovation
  • Market Opportunities
    • Expansion of telepsychiatry services to enhance access to mental health care for bipolar disorder patients
    • Integration of artificial intelligence in diagnostics and treatment planning for bipolar disorder
    • Initiatives to increase mental health awareness and education to reduce stigma associated with bipolar disorder
  • Market Challenges
    • Limited awareness and diagnosis of bipolar disorder among the population hinders market growth
    • High prevalence of side effects and low patient adherence to bipolar disorder medications affect treatment outcomes

Exploring Porter’s Five Forces for the Bipolar Disorder Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Bipolar Disorder Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bipolar Disorder Therapeutics Market

External macro-environmental factors deeply influence the performance of the Bipolar Disorder Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bipolar Disorder Therapeutics Market

The Bipolar Disorder Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bipolar Disorder Therapeutics Market

The Bipolar Disorder Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bipolar Disorder Therapeutics Market

The Bipolar Disorder Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bipolar Disorder Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Mylan N.V., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Bipolar Disorder Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapeutics
    • Anticonvulsants
      • Carbamazepine
      • Lamotrigine
    • Antidepressant Drugs
      • Fluoxetine
      • Paroxetine
      • Sertraline
      • Venlafaxine
    • Antipsychotic Drugs
      • Aripiprazole
      • Olanzapine
      • Quetiapine
      • Risperidone
    • Mood Stabilizers
      • Lamotrigine
      • Lithium Carbonate
      • Valproate Acid
  • Mechanism Of Action
    • GABAergic Agents
    • Glutamatergic Agents
    • Ion Channel Blockers
    • Monoaminergic Drugs
  • Drug Administration Route
    • Intramuscular
    • Intravenous
    • Oral
  • Patient Age Group
    • Adolescent
    • Adult
    • Geriatric
    • Pediatric
  • End User
    • Homecare Settings
    • Hospitals
      • Inpatient
      • Outpatient
    • Specialty Clinics
      • Mood Disorder Clinics
      • Psychiatric Clinics
  • Treatment Duration
    • Acute
    • Maintenance
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Emerging digital health technologies enabling more efficient management of bipolar disorder
5.1.1.2. Growing investment in biotechnology and pharmaceutical R&D driving innovation in bipolar disorder treatments
5.1.1.3. Expansion of healthcare infrastructure and accessibility improving patient outcomes for bipolar disorder
5.1.1.4. Patient advocacy groups influencing the development and approval of new bipolar disorder medications
5.1.2. Restraints
5.1.2.1. Regulatory hurdles and lengthy approval processes for new bipolar disorder therapeutic drugs
5.1.2.2. Insufficient funding and investment in bipolar disorder research and development affecting innovation
5.1.3. Opportunities
5.1.3.1. Expansion of telepsychiatry services to enhance access to mental health care for bipolar disorder patients
5.1.3.2. Integration of artificial intelligence in diagnostics and treatment planning for bipolar disorder
5.1.3.3. Initiatives to increase mental health awareness and education to reduce stigma associated with bipolar disorder
5.1.4. Challenges
5.1.4.1. Limited awareness and diagnosis of bipolar disorder among the population hinders market growth
5.1.4.2. High prevalence of side effects and low patient adherence to bipolar disorder medications affect treatment outcomes
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bipolar Disorder Therapeutics Market, by Therapeutics
6.1. Introduction
6.2. Anticonvulsants
6.2.1. Carbamazepine
6.2.2. Lamotrigine
6.3. Antidepressant Drugs
6.3.1. Fluoxetine
6.3.2. Paroxetine
6.3.3. Sertraline
6.3.4. Venlafaxine
6.4. Antipsychotic Drugs
6.4.1. Aripiprazole
6.4.2. Olanzapine
6.4.3. Quetiapine
6.4.4. Risperidone
6.5. Mood Stabilizers
6.5.1. Lamotrigine
6.5.2. Lithium Carbonate
6.5.3. Valproate Acid
7. Bipolar Disorder Therapeutics Market, by Mechanism Of Action
7.1. Introduction
7.2. GABAergic Agents
7.3. Glutamatergic Agents
7.4. Ion Channel Blockers
7.5. Monoaminergic Drugs
8. Bipolar Disorder Therapeutics Market, by Drug Administration Route
8.1. Introduction
8.2. Intramuscular
8.3. Intravenous
8.4. Oral
9. Bipolar Disorder Therapeutics Market, by Patient Age Group
9.1. Introduction
9.2. Adolescent
9.3. Adult
9.4. Geriatric
9.5. Pediatric
10. Bipolar Disorder Therapeutics Market, by End User
10.1. Introduction
10.2. Homecare Settings
10.3. Hospitals
10.3.1. Inpatient
10.3.2. Outpatient
10.4. Specialty Clinics
10.4.1. Mood Disorder Clinics
10.4.2. Psychiatric Clinics
11. Bipolar Disorder Therapeutics Market, by Treatment Duration
11.1. Introduction
11.2. Acute
11.3. Maintenance
12. Americas Bipolar Disorder Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Bipolar Disorder Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Bipolar Disorder Therapeutics Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
15.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BIPOLAR DISORDER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. BIPOLAR DISORDER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. BIPOLAR DISORDER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BIPOLAR DISORDER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BIPOLAR DISORDER THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY LITHIUM CARBONATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY VALPROATE ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GABAERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GLUTAMATERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ION CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MONOAMINERGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD DISORDER CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PSYCHIATRIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ACUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 96. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 97. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 98. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 100. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 103. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 104. CANADA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 155. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 156. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 157. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 158. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 159. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 160. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 161. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 162. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 163. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 166. CHINA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 167. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 168. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 169. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 170. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 171. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 172. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 173. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 177. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 178. INDIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 190. INDONESIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 191. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 192. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 193. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 194. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 195. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 196. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 197. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 198. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 199. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 201. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 202. JAPAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 213. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 214. MALAYSIA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 226. PHILIPPINES BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 237. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 238. SINGAPORE BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 249. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 250. SOUTH KOREA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 261. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 262. TAIWAN BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 263. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 264. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 265. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 266. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 267. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 268. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 269. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 270. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 271. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 273. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 274. THAILAND BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 285. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 286. VIETNAM BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT DRUGS, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY DRUG ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2030 (USD MILLION)
TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY TREATMENT DURATION, 2018-2030 (USD MILLION)
TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 300. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 301. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2030 (USD MILLION)
TABLE 302. DENMARK BIPOLAR DISORDER THERAPEUTICS MARKET SIZ

Companies Mentioned

The leading players in the Bipolar Disorder Therapeutics market, which are profiled in this report, include:
  • AbbVie Inc.
  • Alkermes plc
  • Allergan plc
  • Amgen Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lundbeck A/S
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • Sunovion Pharmaceuticals Inc.
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Vanda Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.37 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.73 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Bipolar Disorder Therapeutics - Global Strategic Business Report - Product Image

Bipolar Disorder Therapeutics - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Bipolar Disorder Therapeutics Global Market Report 2024 - Product Image

Bipolar Disorder Therapeutics Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Bipolar Disorder (Manic Depression) - Pipeline Insight, 2024 - Product Image

Bipolar Disorder (Manic Depression) - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Bipolar Depression - Pipeline Insight, 2024 - Product Image

Bipolar Depression - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Bipolar Disorder Drug Market

The Bipolar Disorder Drug market is a subset of the Mental Disorders Drugs market, which includes medications used to treat a variety of mental health conditions. Bipolar Disorder Drugs are used to treat the symptoms of bipolar disorder, a mental health condition characterized by extreme shifts in mood, energy, and activity levels. These drugs are typically prescribed to help manage the manic and depressive episodes associated with the disorder. Commonly prescribed Bipolar Disorder Drugs include mood stabilizers, antipsychotics, and antidepressants. The Bipolar Disorder Drug market is highly competitive, with a range of pharmaceutical companies offering products to treat the condition. Some of the major players in the market include Eli Lilly, Pfizer, GlaxoSmithKline, AstraZeneca, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.